natera inc - NTRA
NTRA
Close Chg Chg %
363.76 -53.09 -14.59%
Closed Market
310.67
-53.09 (14.59%)
Volume: 5.78M
Last Updated:
Nov 6, 2026, 4:00 PM EDT
Company Overview: natera inc - NTRA
NTRA Key Data
| Open $319.99 | Day Range 304.00 - 327.53 |
| 52 Week Range 181.00 - 437.41 | Market Cap $56.36B |
| Shares Outstanding 144.14M | Public Float 135.69M |
| Beta 1.55 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.37 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.97M |
NTRA Performance
| 1 Week | -25.01% | ||
| 1 Month | -22.47% | ||
| 3 Months | -3.55% | ||
| 1 Year | 55.67% | ||
| 5 Years | 167.89% |
NTRA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
25
Full Ratings ➔
About natera inc - NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
NTRA At a Glance
Natera, Inc.
Building A, 13011 McCallen Pass
Austin, Texas 78753
| Phone | 1-650-980-9190 | Revenue | 2.31B | |
| Industry | Biotechnology | Net Income | -208,160,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 35.901% | |
| Fiscal Year-end | 12 / 2026 | Employees | 6,140 | |
| View SEC Filings |
NTRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.582 |
| Price to Book Ratio | 18.688 |
| Price to Cash Flow Ratio | 145.48 |
| Enterprise Value to EBITDA | -116.025 |
| Enterprise Value to Sales | 13.208 |
| Total Debt to Enterprise Value | 0.007 |
NTRA Efficiency
| Revenue/Employee | 375,588.436 |
| Income Per Employee | -33,902.28 |
| Receivables Turnover | 7.777 |
| Total Asset Turnover | 1.10 |
NTRA Liquidity
| Current Ratio | 3.393 |
| Quick Ratio | 3.238 |
| Cash Ratio | 2.439 |
NTRA Profitability
| Gross Margin | 64.674 |
| Operating Margin | -13.27 |
| Pretax Margin | -11.625 |
| Net Margin | -9.026 |
| Return on Assets | -9.926 |
| Return on Equity | -14.317 |
| Return on Total Capital | -10.803 |
| Return on Invested Capital | -13.331 |
NTRA Capital Structure
| Total Debt to Total Equity | 12.519 |
| Total Debt to Total Capital | 11.126 |
| Total Debt to Total Assets | 8.548 |
| Long-Term Debt to Equity | 6.918 |
| Long-Term Debt to Total Capital | 6.149 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Natera Inc - NTRA
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 820.22M | 1.08B | 1.70B | 2.31B | |
Sales Growth
| +31.13% | +31.99% | +56.75% | +35.90% | |
Cost of Goods Sold (COGS) incl D&A
| 456.26M | 589.83M | 673.75M | 814.65M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 30.47M | 38.62M | 30.97M | 43.48M | |
Depreciation
| 30.47M | 38.62M | 30.97M | 37.86M | |
Amortization of Intangibles
| - | - | - | 5.62M | - |
COGS Growth
| +43.29% | +29.28% | +14.23% | +20.91% | |
Gross Income
| 363.97M | 492.74M | 1.02B | 1.49B | |
Gross Income Growth
| +18.53% | +35.38% | +107.65% | +45.77% | |
Gross Profit Margin
| +44.37% | +45.52% | +60.30% | +64.67% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 895.72M | 936.31M | 1.25B | 1.80B | |
Research & Development
| 307.13M | 318.00M | 404.14M | 624.11M | |
Other SG&A
| 588.59M | 618.31M | 841.31M | 1.17B | |
SGA Growth
| +21.10% | +4.53% | +33.02% | +44.32% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 9.29M | 2.68M | 3.90M | |
EBIT after Unusual Expense
| (541.04M) | (446.24M) | (222.29M) | (309.91M) | |
Non Operating Income/Expense
| 3.54M | 24.35M | 43.25M | 45.89M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 9.32M | 12.64M | 10.69M | 4.07M | |
Interest Expense Growth
| +12.21% | +35.62% | -15.45% | -61.92% | |
Gross Interest Expense
| 9.32M | 12.64M | 10.69M | 4.07M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (546.82M) | (434.53M) | (189.73M) | (268.09M) | |
Pretax Income Growth
| -16.07% | +20.54% | +56.34% | -41.30% | |
Pretax Margin
| -66.67% | -40.14% | -11.18% | -11.63% | |
Income Tax
| 978.00K | 271.00K | 695.00K | (59.93M) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (547.80M) | (434.80M) | (190.43M) | (208.16M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (547.80M) | (434.80M) | (190.43M) | (208.16M) | |
Net Income Growth
| -16.13% | +20.63% | +56.20% | -9.31% | |
Net Margin Growth
| -66.79% | -40.16% | -11.22% | -9.03% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (547.80M) | (434.80M) | (190.43M) | (208.16M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (547.80M) | (434.80M) | (190.43M) | (208.16M) | |
EPS (Basic)
| -5.5666 | -3.781 | -1.5268 | -1.5225 | |
EPS (Basic) Growth
| -6.87% | +32.08% | +59.62% | +0.28% | |
Basic Shares Outstanding
| 98.41M | 115.00M | 124.72M | 136.72M | |
EPS (Diluted)
| -5.5666 | -3.781 | -1.5268 | -1.5225 | |
EPS (Diluted) Growth
| -6.87% | +32.08% | +59.62% | +0.28% | |
Diluted Shares Outstanding
| 98.41M | 115.00M | 124.72M | 136.72M | |
EBITDA
| (501.28M) | (404.95M) | (191.33M) | (262.53M) | |
EBITDA Growth
| -18.98% | +19.22% | +52.75% | -37.21% | |
EBITDA Margin
| -61.11% | -37.41% | -11.27% | -11.38% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 416.386 | |
| Number of Ratings | 25 | Current Quarters Estimate | -0.13 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -1.57 | |
| Last Quarter’s Earnings | -0.42 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.52 | Next Fiscal Year Estimate | -0.428 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 19 | 14 | 20 | 21 |
| Mean Estimate | -0.13 | -0.28 | -1.57 | -0.43 |
| High Estimates | 0.32 | -0.15 | -1.17 | 0.61 |
| Low Estimate | -0.40 | -0.44 | -1.89 | -1.67 |
| Coefficient of Variance | -143.55 | -35.04 | -12.23 | -143.10 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 18 | 18 | 17 |
| OVERWEIGHT | 4 | 4 | 4 |
| HOLD | 2 | 2 | 3 |
| UNDERWEIGHT | 1 | 1 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Natera Inc - NTRA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Natera Inc - NTRA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 5, 2026 | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | 46,566 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $388.03 per share | 18,069,004.98 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 102,763 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $409.46 per share | 42,077,337.98 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 103,283 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $408.08 per share | 42,147,726.64 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 103,691 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $406.94 per share | 42,196,015.54 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 104,123 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $405.26 per share | 42,196,886.98 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 104,323 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $400.29 per share | 41,759,453.67 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 104,733 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $388.2 per share | 40,657,350.60 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 102,643 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $410.72 per share | 42,157,532.96 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 101,323 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $416.45 per share | 42,195,963.35 |
| Nov 5, 2026 | Stephen Leonard Chapman CEO AND PRESIDENT; Director | 91,211 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $387.9 per share | 35,380,746.90 |
| Nov 5, 2026 | Stephen Leonard Chapman CEO AND PRESIDENT; Director | 87,431 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $415.64 per share | 36,339,820.84 |
| Nov 5, 2026 | Matthew Rabinowitz EXECUTIVE CHAIRMAN; Director | 2,117,659 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $388.2 per share | 822,075,223.80 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 102,523 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $411.73 per share | 42,211,794.79 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 102,323 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $414.16 per share | 42,378,093.68 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 101,563 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $415.52 per share | 42,201,457.76 |
| Nov 5, 2026 | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | 102,403 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $412.88 per share | 42,280,150.64 |
| Nov 5, 2026 | John Fesko PRESIDENT, CHIEF BUS. OFFICER | 195,276 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $400.29 per share | 78,167,030.04 |
| Nov 5, 2026 | Stephen Leonard Chapman CEO AND PRESIDENT; Director | 90,297 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $400.29 per share | 36,144,986.13 |
| Nov 5, 2026 | Jonathan Sheena Director | 217,574 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $400.29 per share | 87,092,696.46 |
| Nov 5, 2026 | Jonathan Sheena Director | 217,683 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $388.2 per share | 84,504,540.60 |
Natera Inc in the News
Complaint letter filed with SEC regarding Natera’s promotion of prenatal screening technology
A complaint to the SEC alleges that Natera misled investors and others about its prenatal screening product.